Hong Kong
· Delayed Price · Currency is HKD Shanghai Fosun Pharmaceutical (Group) Company Description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally.
The company’s product pipeline includes HLX15, a recombinant anti-CD38 human monoclonal antibody injection for treatment of multiple myeloma; HLX13, an anti-CTLA-4 human monoclonal antibody for the treatment of melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, and esophageal squamous cell cancer; SZEY-2108 for the treatment of carbapenem resistant enterobacteriaceae (CRE) infection; XH-S003 for the treatment of IgA nephropathy and other glomerular diseases; HLX43, an antibody-drug for the treatment of metastatic solid tumors; XS-03 for the treatment of RAS-mutated advanced solid tumor; OP0595, a nacubactam for the treatment of aerobic gram-negative bacteria; XH-S002 for the treatment of ischemic stroke and transient ischemic attack which are in Phase I; HLX26, anti-LAG-3 humanized monoclonal antibody injection for the treatment of metastatic colorectal cancer; FCN-338 for the treatment of myeloid malignancies; FCN-159 for the treatment of langerhans cell histiocytosis; HLX208, a BRAF V600E inhibitor for the treatment of non-small cell lung cancer which are in phase II; FS-1502, a HER2 humanized monoclonal antibody-monomethyl auristatin F injection for the treatment of HER2-positive locally advanced or metastatic breast cancer; FCN-159 for the treatment of neurofibromatosis; ET-26, a methoxyetomidate hydrochloride for the treatment of general anesthesia which are in phase III.
It engages in the import and export of medical equipment; provision of related and other consulting services; medical devices and diagnosis products, and healthcare service; and investment management, as well as involves in the retail and wholesale distribution of medicines.
The company was founded in 1994 and is based in Shanghai, China.
| Country | China |
| Founded | 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 40,370 |
| CEO | Deyong Wen |
Contact Details
Address: Building A Shanghai, 200233 China | |
| Phone | 86 21 3398 7000 |
| Website | fosunpharma.com |
Stock Details
| Ticker Symbol | 2196 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100001M79 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wenjie Zhang | Executive President and Co-Chief Executive Officer of Innovative Drug Division |
| Wang Xingli M.D., Ph.D. | Executive President, Co-Chief Executive Officer of Innovative Medicines Division and CEO of Global Research & Development Center |
| Jing Li | Executive President and Chief Executive Officer of Established Medicines Manufacturing and Supply Division |
| Deyong Wen | Joint President,Chief Executive Officer and Executive Director |
| Kexin Wang | Executive Co-Chairman |
| Yifang Wu | Executive Chairman |
| Xiaohui Guan | Executive Vice Chairman |
| Rongli Feng | Executive President and Chief Human Resources Office |
| Zhanyu Chen | Senior Vice President and Chief Financial Officer |
| Jia Yan | Director of the Accounting Department |